upadacitinib (ABT-494)

AbbVie
Biotech

AbbVie’s JAK1 upadacitinib hits arthritis, but death registered in test

AbbVie has scored another key trial win with its JAK1 inhibitor upadacitinib, but a death and pulmonary embolism take some of the shine off the data.
Ben Adams Dec 20, 2017 8:50am
skin close-up

AbbVie preps JAK atopic dermatitis candidate for phase 3

Sep 8, 2017 10:49am